7/11/2023 | DD | Clovis Oncology’s Chapter 11 liquidation plan effective as of July 10
|
6/30/2023 | DD | Clovis Oncology debtors report operating results for May
|
6/16/2023 | DD | Clovis Oncology receives confirmation of amended Chapter 11 plan
|
6/12/2023 | DD | Clovis: U.S. trustee takes issue with fees under proposed settlement
|
6/7/2023 | DD | Clovis reaches settlement with secured lenders, creditors committee
|
6/6/2023 | DD | Clovis’ attempt to disband equity committee denied by court
|
6/5/2023 | DD | Clovis Oncology’s plan, disclosure statement hearing continued
|
6/2/2023 | DD | Clovis Oncology debtors report operating results for April
|
6/2/2023 | DD | Clovis, creditors object to equity committee’s motion for mediation
|
6/1/2023 | DD | Clovis Oncology official equity committee calls for mediation
|
5/30/2023 | DD | Clovis gives plan voting results, equity committee files objection
|
5/24/2023 | DD | Clovis Oncology’s Chapter 11 plan draws objection from U.S. trustee
|
5/18/2023 | DD | Clovis equity holders respond to motion to disband committee
|
5/11/2023 | DD | Clovis hearings set to consider plan confirmation, equity committee
|
5/10/2023 | DD | Clovis’ effort to disband equity committee gets support from creditors
|
5/8/2023 | DD | Clovis Oncology: U.S. trustee appoints official equity committee
|
5/5/2023 | DD | Clovis Oncology wants to disband equity committee with trustee saying ‘not so fast’
|
5/3/2023 | DD | Clovis Oncology debtors report operating results for March
|
5/2/2023 | DD | Clovis Oncology closes sale of Rubraca assets to pharma& Schweiz
|
4/28/2023 | DD | Clovis Oncology wins three-month extension of exclusive plan periods
|
4/21/2023 | DD | Clovis Oncology receives interim approval of disclosure statement
|
4/13/2023 | DD | Clovis Oncology receives OK to sell Rubraca assets to pharma& Schweiz
|
4/11/2023 | DD | Clovis Oncology eyes three-month extension of exclusive plan periods
|
4/4/2023 | DD | Clovis Oncology takes in $116 million winning bid for assets
|
4/3/2023 | DD | Clovis Oncology disclosure statement hearing moved to April 11
|
3/31/2023 | DD | Clovis Oncology debtors report operating results for February
|
3/30/2023 | DD | Clovis Oncology disclosure statement draws committee objection
|
3/29/2023 | DD | Clovis Oncology disclosure statement draws U.S. trustee objection
|
3/22/2023 | DD | Clovis Oncology gets court approval to sell FAP-2286 to Novartis
|
3/20/2023 | DD | Clovis Oncology disclosure statement hearing scheduled for April 4
|
3/17/2023 | DD | Clovis Oncology receives approval of employee bonus program
|
3/15/2023 | DD | Clovis files Chapter 11 plan of liquidation and disclosure statement
|
3/14/2023 | DD | Clovis gets approval of $5.17 million in incremental DIP financing
|
3/8/2023 | DD | Clovis cancels auction for FAP-2286; will seek sale to Novartis
|
3/2/2023 | DD | Clovis Oncology debtors report operating results for January
|
2/28/2023 | DD | Clovis Oncology’s employee bonus program draws U.S. trustee objection
|
2/27/2023 | BKDD | Clovis Oncology seeks $5.17 million of incremental DIP financing
|
2/9/2023 | DD | Clovis Oncology reports $133.46 million net loss for December
|
1/24/2023 | DD | Clovis get approval of $75 million DIP loan and bid procedures
|
1/17/2023 | DD | Clovis’ proposed DIP loan, bid procedures draw objections
|
12/22/2022 | DD | Clovis Oncology trustee forms unsecured creditors committee
|
12/16/2022 | BKCVDDEMHY | Prospect News reports six new defaults for Dec. 8-Dec. 14
|
12/16/2022 | DD | Clovis opts for DIP facility via Sixth Street following auction
|
12/13/2022 | DD | Clovis Oncology details terms of proposed $75 million DIP facility
|
12/12/2022 | BKCVDD | Clovis Oncology files Chapter 11 bankruptcy, plans to sell assets
|
11/9/2022 | CVDD | Clovis Oncology bankruptcy in near term looks ‘increasingly probable’
|
11/25/2020 | CVLM | Clovis enters exchange agreement with holder of 4.5% convertibles
|
11/5/2020 | CVLM | Clovis enters exchange agreement with holder of 4.5% convertibles
|
4/20/2020 | CV | Market Commentary: 2U convertible offering eyed; Scorpio Tankers expands as oil collapses; Clovis active
|
4/14/2020 | CVLM | Clovis enters exchange agreement with holder of 2.5% convertibles
|
1/7/2020 | CV | Market Commentary: Luckin Coffee, Alibaba exchangeables on deck; Apellis expands ‘massively’; Clovis mixed
|
1/7/2020 | CVLM | Clovis to buy back $123.42 million 4.5% convertibles due 2024
|
1/7/2020 | CV | Market Commentary: Morning Commentary: Apellis expands ‘massively’; Clovis buys back convertible notes
|
12/2/2019 | CV | Market Commentary: Convertibles secondary slow; Intercept, Clovis bull run continues; Akamai notes active
|
8/22/2019 | CV | Clovis partial greenshoe lifts 4.5% convertibles to $263 million
|
8/9/2019 | CV | Market Commentary: Convertibles issuance tops $3 billion for week, Clovis, BlackLine expand; Ironwood drops
|
8/9/2019 | CV | Market Commentary: Morning Commentary: Clovis, BlackLine price; primary rounds out busiest week of year
|
8/8/2019 | CVLM | Clovis Oncology to buy back $190.3 million 2.5% convertibles Aug. 13
|
8/8/2019 | CV | New Issue: Clovis Oncology prices $250 million 4.5% five-year convertibles, up 25%
|
8/8/2019 | CV | Market Commentary: Morning Commentary: BlackLine, Clovis Oncology convertibles on tap; four deals price
|
8/7/2019 | CV | Market Commentary: Alteryx, Ironwood, Mesa Labs eyed; CorEnergy, BlackLine, Clovis on tap; Snap skyrockets
|
8/7/2019 | CV | Clovis Oncology talks $225 million five-year convertibles to yield 4%-4.5%, up 25%-30%
|
7/23/2019 | CV | Market Commentary: Tesla in focus pre-earnings; recent convertible sees large block trade; Clovis active
|
6/17/2019 | CV | Market Commentary: Change Healthcare on tap; DISH Network expands; Array skyrockets outright on buyout
|
6/17/2019 | CV | Market Commentary: Morning Commentary: Secondary trading light; health care sector boosted by Array buyout
|
1/3/2019 | CV | Market Commentary: Apple suppliers Microchip Technology, Western Digital notes active; Ensco better bid
|
12/4/2018 | CV | Market Commentary: RH ‘explores’ new convertible offering, existing notes mixed; Clovis expansion continues
|
12/3/2018 | CV | Market Commentary: Tesaro convertibles active, up on buyout by GlaxoSmithKline; iQIYI, Liberty Media gain
|
11/6/2018 | CV | Market Commentary: Booking Holdings convertibles dominate; Invacare slips; Clovis up; Weatherford active
|
10/31/2018 | CV | Market Commentary: Clovis convertibles clobbered; Exact Sciences, FireEye improve; Weatherford rebounds
|
10/22/2018 | CV | Market Commentary: Weibo improves on China stock rally; Clovis convertibles mixed; Hope Bancorp drops
|
5/1/2018 | CV | Market Commentary: Transocean convertibles in spotlight; Marriott, Arconic remain in focus; EFII active
|
4/30/2018 | CV | Market Commentary: Marriott Vacations active on ILG acquisition; Arconic expands; Molina notes volatile
|
4/23/2018 | CV | Market Commentary: JPMorgan on tap; Clovis contraction continues; Insmed improves; Ctrip.com, NXP active
|
4/20/2018 | CV | Market Commentary: New convertible paper quiet; Clovis contracts; Ionis, NXP in focus in secondary market
|
4/20/2018 | CV | Market Commentary: Morning Commentary: New convertible paper quiet in early trading; Clovis moves lower
|
4/18/2018 | CV | Market Commentary: Paratek, Ship Finance convertibles on tap; Jersey Industries, Deutsche Bank deals eyed
|
4/18/2018 | CV | Market Commentary: Morning Commentary: Jersey Industries, Deutsche Bank deals on tap; Red Hat active
|
4/17/2018 | CV | Market Commentary: South Jersey, Deutsche on tap; Clovis convertibles ‘well received’; oil still catching bids
|
4/17/2018 | CV | Market Commentary: Morning Commentary: Clovis convertibles ‘well received,’ expand on market debut
|
4/16/2018 | CV | New Issue: Clovis prices upsized $300 million seven-year convertibles to yield 1.25%, up 40%
|
4/16/2018 | CV | Market Commentary: Clovis Oncology deal looks ‘cheap,’ existing convertible trades down; Lumentum drops
|
4/16/2018 | CV | Market Commentary: Morning Commentary: Clovis Oncology launches $200 million offering; deal looks ‘cheap’
|
4/16/2018 | CV | Clovis talks $200 million seven-year convertible notes to yield 1% to 1.5%, up 35% to 40%
|
6/20/2017 | CV | Market Commentary: Energy names sink with drop in oil prices; Tesla edges up; Synaptics, Teladoc notes on tap
|
6/20/2017 | CV | Market Commentary: Morning Commentary: Energy names sink outright with lower oil prices; Clovis Oncology quiet, gains
|
6/19/2017 | CV | Market Commentary: Clovis Oncology convertibles jump over 25 points on positive trial data; biotech follows
|
6/19/2017 | CV | Market Commentary: Morning Commentary: Clovis Oncology dominates trading, convertibles jump over 25 points on data
|
1/5/2017 | CV | Market Commentary: Colony Starwood’s new deal trades above par; Michelin taps the market; Clovis on the rise
|
8/24/2016 | PP | Market Commentary: Dycom lower outright, adds on swap; Clovis eyed for potential drug approval; REITs for sale
|
8/24/2016 | CV | Market Commentary: Dycom lower outright, adds on swap; Clovis eyed for potential drug approval; REITs for sale
|
8/24/2016 | CV | Market Commentary: Morning Commentary: Dycom lower outright but expands on swap; Clovis shares higher on drug outlook
|
8/22/2016 | PP | Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
|
8/22/2016 | CV | Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
|
6/29/2016 | CV | Market Commentary: Tesaro surges after positive drug data; Tesla lower; Intercept Pharmaceuticals on tap
|
6/29/2016 | CV | Market Commentary: Morning Commentary: Tesaro surges after positive drug study data; Tesla lower; equities on the rise
|
4/13/2016 | PP | Market Commentary: Health care convertibles mixed; energy ‘trickles back’; China-related names active on data
|
4/13/2016 | CV | Market Commentary: Health care convertibles mixed; energy ‘trickles back’; China-related names active on data
|
4/13/2016 | DD | Market Commentary: Distressed energy debt rallies on output cut hopes, oil price boost; healthcare converts underperform
|
4/12/2016 | HY | Market Commentary: Distressed energy debt rallies on output cut hopes; healthcare convertibles underperform
|
4/12/2016 | PP | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
4/12/2016 | CV | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
4/12/2016 | CV | Market Commentary: Morning Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake gains
|
11/17/2015 | PP | Market Commentary: SunEdison gaps lower again; new Black Hills mandatory looks cheap; Clovis slide continues
|
11/17/2015 | CV | Market Commentary: SunEdison gaps lower again; new Black Hills mandatory looks cheap; Clovis slide continues
|
11/17/2015 | CV | Market Commentary: Morning Commentary: Planned Black Hills mandatory looks 2% cheap; Clovis Oncology slide continues
|
11/16/2015 | PP | Market Commentary: Convertibles steady after Paris terror attacks; Clovis collapses on drug-review setback
|
11/16/2015 | CV | Market Commentary: Convertibles steady after Paris terror attacks; Clovis collapses on drug-review setback
|
11/16/2015 | CV | Market Commentary: Morning Commentary: Clovis collapses on drug-review setback; Vipshop extends losses; Illumina up
|
4/13/2015 | PP | Market Commentary: Clovis jumps outright, on swap; Medicines, Horizon Pharma trade; Asian internet names eyed
|
4/13/2015 | CV | Market Commentary: Clovis jumps outright, on swap; Medicines, Horizon Pharma trade; Asian internet names eyed
|
10/28/2014 | PP | Market Commentary: Twitter drops outright, mixed to lower on hedge; Medicines opens up; Synergy to price
|
10/28/2014 | CV | Market Commentary: Twitter drops outright, mixed to lower on hedge; Medicines opens up; Synergy to price
|
9/9/2014 | CV | Clovis greenshoe exercised, lifts 2.5% convertibles to $287.5 million
|
9/4/2014 | PP | Market Commentary: New Clovis, Depomed upsized, add on debut; Electronics For Imaging edges up; Teslas mixed
|
9/4/2014 | CV | Market Commentary: New Clovis, Depomed upsized, add on debut; Electronics For Imaging edges up; Teslas mixed
|
9/4/2014 | CV | Market Commentary: Morning Commentary: Clovis, Depomed add with underlying shares mixed; Electronics For Imaging gains
|
9/3/2014 | CV | New Issue: Clovis Oncology prices upsized $250 million 2.5% seven-year convertibles, up 37.5%
|
9/3/2014 | PP | Market Commentary: Planned Depomed, Electronics For Imaging add in the gray; Huron Consulting notes on tap
|
9/3/2014 | CV | Market Commentary: Planned Depomed, Electronics For Imaging add in the gray; Huron Consulting notes on tap
|
9/3/2014 | CV | Market Commentary: Morning Commentary: New deals in focus; Clovis Oncology shares sharply lower; Exelixis slips
|
9/2/2014 | CV | Clovis Oncology plans $200 million seven-year convertibles to yield 2.5%-3%, up 32.5%-37.5%
|
9/2/2014 | PP | Market Commentary: Endo, Gilead weaker; primary market sees Electronics For Imaging, Depomed, Clovis on tap
|
9/2/2014 | CV | Market Commentary: Endo, Gilead weaker; primary market sees Electronics For Imaging, Depomed, Clovis on tap
|
4/4/2012 | PP | Clovis Oncology prices $75 million public offering of stock at $20.00
|